Movatterモバイル変換


[0]ホーム

URL:


US3926188A - Laminated drug dispenser - Google Patents

Laminated drug dispenser
Download PDF

Info

Publication number
US3926188A
US3926188AUS523720AUS52372074AUS3926188AUS 3926188 AUS3926188 AUS 3926188AUS 523720 AUS523720 AUS 523720AUS 52372074 AUS52372074 AUS 52372074AUS 3926188 AUS3926188 AUS 3926188A
Authority
US
United States
Prior art keywords
drug
dispenser
lamina
agent
laminate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US523720A
Inventor
Richard W Baker
Robert M Gale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza CorpfiledCriticalAlza Corp
Priority to US523720ApriorityCriticalpatent/US3926188A/en
Priority to GB4228975Aprioritypatent/GB1477813A/en
Priority to DE2549856Aprioritypatent/DE2549856C2/en
Priority to IT69740/75Aprioritypatent/IT1050619B/en
Priority to CA239,459Aprioritypatent/CA1056685A/en
Priority to JP50136148Aprioritypatent/JPS6059203B2/en
Priority to CH1472575Aprioritypatent/CH634226A5/en
Priority to SE7512744Aprioritypatent/SE439432B/en
Priority to MX6132Aprioritypatent/MX158867A/en
Priority to FR7534821Aprioritypatent/FR2290891A1/en
Priority to MX161923Aprioritypatent/MX158868A/en
Application grantedgrantedCritical
Publication of US3926188ApublicationCriticalpatent/US3926188A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

A three layer laminate drug dispenser comprising a core lamina of a crystalline drug of low water solubility dispersed homogeneously in a polymer matrix of permeability, P, to the drug, the lamina having a thickness, 2t, and a surface area, A, interposed between outer laminas made of a drug release rate controlling polymer of permeability, P'', to the drug, each outer lamina having a thickness, t'',and the combined, exposed surface area of the outer laminas being A'' wherein the expression

and the expression

k being a constant whose value is dependent upon the geometrical shape of the dispenser.

Description

United States Patent 1191 Baker et al.
[ Dec. 16, 1975 1 1 LAMINATED DRUG DISPENSER [75] Inventors: Richard W. Baker, Bend, Oreg.; Robert M. Gale, San Jose, Calif.
[52] US. Cl. 128/260; 424/19; 128/213 [51] Int. Cl. A61M 31/00; A61K 27/12 [58] Field of Search 128/156, 260, 268, 2 R,
[56] References Cited UNITED STATES PATENTS 2,928,770 3/1960 Bardani 424/21 3,184,386 5/1965 Stephenson 424/21 3,416,530 12/1968 Ness 128/260 3,618,604 11/1971 Ness 128/260 3,625,214 12/1971 Higuchi 128/260 3,797,485 3/1974 Urquhart 128/213 3,851,648 12/1974 Brooke 128/260 Primary ExaminerAldrich F. Medbery Attorney, Agent, or Firm-Thomas E. Ciotti; Paul L. Sabatine', Edward L. Mandell 5 7 ABSTRACT A three layer laminate drug dispenser comprising a core lamina of a crystalline drug of low water solubility dispersed homogeneously in a polymer matrix of permeability, P, to the drug, the lamina having a thickness, 2!, and a surface area, A, interposed between outer laminas made of a drug release rate controlling polymer of permeability, P, to the drug, each outer lamina having a thickness, z',and the combined, exposed surface area of the outer laminas being A wherein the expression and theexpression A P r 2; (DA 3 I 13 Claims, 5 Drawing Figures U.S. Patent De c. 16, 1975 Sheet 1 of2 3,926,188
FIG.|
FIG.2
DISPENSERS 0F EXAMPLE I TIME HR.)
US. Patent Dec.16, 1975 Sheet2of2 3,926,188
5 7| 2 2 5 2 2 2w 2 DI Wu 0 VA 3 CL I F 0 G 0 l S R F E O 5 8 2 N l C... DI 0 8 0 D I 5 7| 0 5 5 2 0 0 0 0 0 0O 0 6 M m m 00 6 4 DISPENSERS 0F EXAMPLE 5 I60 I I I 2'0 2:305 MC; $5 5m TIME HR.)
LAMINATED DRUG DISPENSER BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a laminated dispenser for dispensing active agents by a diffusion mechanism. More specifically it relates to dispensers comprising a three layer sandwich-type laminate which dispense crystalline drugs of low water solubility.
2. Description of the Prior Art Numerous sustained release dispensers, particularly ones for dispensing drugs, have been developed recently which comprise an active agent which is confined within a polymer and which dispense an agent by a diffusion mechanism in which the agent permeates through the polymer. The aim of these devices is to dispense the drug at a more or less constant rate for a prolonged period of time which results in improved therapy compared to drugs delivered by periodic ingestion of pills, injections or drops. Basically such dispensers are of two types: monolithic and reservoir. In a monolithic device the drug or other active agent is dispersed in a polymer which is permeable to the drug. The time rate of release of agent from such devices has been studied and reported. It is proportional to time A plot of release rate versus time for a monolithic device gives a curve which starts at a high rate and continuously declines. Notwithstanding this varying release rate, monolithic devices have the commercial attractiveness of being inexpensive to make.
T. Higuchi, J. Plzurm. Sci., 50, 874 (I961); T. J. Roseman et al.. J. Plmrm. Sci., 61, 46 (1972); and H. K. Lonsdale. R. W. Baker. Controlled Release of Biologically Active Agents, Ed. C. Tanquery. Plenum Press, New York (1974) In a reservoir device the active agent is confined within a container formed of a polymer which is permeable to the agent. The agent may be neat or combined with a solid or liquid carrier. In copending, commonly assigned applications Ser. Nos. 42,786 and 185,208, filed June 2, 1970 and Sept. 30, 1971, respectively, embodiments of reservoir devices in which the agent release is substantially constant are disclosed. The two basic features of those embodiments which permit such release are: formulating the agent in a liquid or solid carrier whose permeability to the drug is greater than the permeability of the polymer defining the container to the agent; and maintaining the concentration of the agent in the carrier at saturation for the effective dispensing lifetime of the device. For some agents such reservoir embodiments are the only type of diffusion device for dispensing the agent at a practical controlled rate. Such embodiments also provide the advantages of providing a substantially constant release of agent-- which is an important factor as regards efficacy and safety in many therapeutic regimens. The disadvantages of reservoir devices as compared to monolithic devices is economic--the former being more complex and hence more costly to make than the latter.
SUMMARY OF THE INVENTION provided there is a particular correlation between the respective permeabilities, thicknesses and exposed surface areas of the core lamina and the outer lamina(s).
0 having a permeability, P. to the drug, a thickness, 1,
and an exposed surface area, A, .from which drug is released wherein is greater than about 2 and is at least three times k being a constant whose value is dependent upon the geometrical shape of the laminate.
Preferably is greater than 3 and is at least 10 times L. 1 i P I The laminated drug dispenser of this invention may be in the form of a three layered sandwich or in the form of a concentric laminate. This type of device combines the good drug release kinetics of the reservoir devices with the ease and cheapness of manufacture of monolithic devices.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings like reference numerals refer to like parts, and:
FIG. 1 is a cross-sectional view of a drug dispenser of this invention;
FIG. 2 is a graphical representation of the release rates of the devices described in Example 1, infra;
FIG. 3 is a graphical representation of the release rates of the devices dese'fibed in Example 2, infra;
FIG. 4 is a graphical Representation of the release rates of tl ie devices descflled in Example 3, infra; and
FIG. 5 l an elevational perspective view of another drug dlfir of this invlition.
DESCRIPTION OF THE PREFERRED EMBODIMENTS FIG. 1 illustrates a drug dispenser, generally designated 10, of this invention. Dispenser is a three layer sandwich-type laminate in the shape of a thin, circular disc comprising a core lamina 11 sandwiched between twoouter laminas 12,13. Core lamina 11 consists of solid particles ofdrug 14 dispersed within amatrix material 15.Material 15 has a permeability, P, and core lamina 11 has a thickness, 21. Theedge 16 of core lamina 11 defines the surface area, A, thereof which is exposed to the environment.
Outer laminas 12,13 each have a thickness, t, and a permeability, P, to the drug.Surfaces 17,18 oflaminas 12,13 define a combined surface area, A, thereof which is exposed to the environment. (The area defined by the axial edges oflaminas 12,13 is also exposed but is negligible relative to area A'.)
Dispenser 10 releasesdrug 14 atsurfaces 16,17 and 18 by a diffusion mechanism. Drug molecules initially dissolve inmatrix material 15 and permeate therethrough either to exposedsurface 16 or toouter laminas 12,13 and therethrough to exposedsurfaces 17,18.
The molecules which reach exposedsurfaces 16,17,18 are removed or cleared therefrom through contact with body fluids and/or body tissue. When the respective permeabilities and thicknesses of core lamina 11 andouter laminas 12,13 are correlated as set forth above, that is is greater than about 2, drug will be released fromsurfaces 17,18 at a substantially constant rate as long asmatrix material 15 is saturated with the drug. In contrast, drug is released fromedge 16 at a constantly declining rate proportional to time"? However, by correlating the permeabilities, thicknesses and exposed surface areas of core lamina l 1 andouter laminas 12,13 as set forth above, the amount of drug released fromedge 16 is substantially less than the amount of drug released fromsurfaces 17,18. Accordingly, the overall release rate from dispenser 10 is dominated by the release rate of drug fromsurfaces 17,18 and thus the overall release rate approximates the substantially constant release rate from those surfaces. In this respect, the greater the magnitude of and the greater the difference between the magnitude of the expression and the magnitude of the expression the closer is this approximation. If
is less than 2, the outer membranes do not control the drug release rate which declines proportional to time? If the area of exposed core is too high or the permeability of the core is too high and release of drug from the edge predominates and again the release rate declines proportional to time. In the intermediate region, how ever, which is the subject of this invention, neither of these effects predominates and drug release is almost constant with time. The release rates of these laminates are, of course, not as constant as the release rates of comparable prior art reservoir devices in which the core is not exposed to the environment. However, for many therapies the degree of release rate constancy afforded by these laminates is acceptable. Thus they provide a viable, less expensive alternative to the reservoir devices in such instances.
FIG. 5 illustrates another drug dispenser, generally designated 19, of the invention.Dispenser 19 is a concentric-type laminate in the shape of a cylinder comprising acylindrical core lamina 20 and an outerconcentric lamina 21 which covers the axial surface ofcore lamina 20.Core lamina 20, like core lamina 11, comprises particles ofdrug 14 dispensed within amatrix material 15. It is functionally equivalent to core lamina 1 1. The ends 22,23 ofcore lamina 20 define the surface area, A, thereof which is exposed to the environment.Core lamina 20 has a diameter, 2!. Outerconcentric lamina 21 has a permeability, P, to the drug and has a thickness, t.Lamina 21 is functionally identical tolaminas 12,13 and may be made from the same materials as the latter. Theaxial surface 24 oflamina 21 defines the surface area, A, thereof which is exposed to the environment. (The area defined by the radial edges oflamina 21 is also exposed but is negligible relative to area A'.)
Dispenser 19releases drug 14 atsurfaces 22,23,24 by a diffusion mechanism identical to that described above with respect to dispenser 10. The correlations between the thicknesses, permeabilities and exposed surface areas oflaminas 20,21 ofdispenser 19 required to permitdispenser 19 to release drug at a substantially constant rate are the same as those described above. with respect to dispenser 10.
Drug 14 is solid (crystalline) and should have a low water solubility. Low water solubility is a requirement so that the drug does not function to any significant extent as an osmotic attractant to imbibe water from the use environment into core lamina 11. If substantial water is imbibed, thedrug 14 may be released by an osmotic bursting mechanism rather than a diffusion mechanism. This would affect the release rate of drug in an undesirable manner. The degree of water solubility will in many-instances depend on the permeability ofmatrix material 15 to water. Ifmaterial 15 has a high permeability tovwater, the water solubility of the drug should be correspondingly low and vice versa. Drugs which are less than about 4% by weight soluble in water are preferred.
The particle size of drug- 14 is notcritical. Particle sizes in the-range of l to 20p. will normally be used since they are easy to handle and may be readily dispersed homogeneously in matrix material by conventional techniques.
The loading ofdrug 14 in core lamina 11 is important because it may affect the permeability of core lamina 11 to the drug. At high drug loadings (greater than about 25% by weight) lamina 11 has a tendency to become microporous over the. devices lifetime. This occurs because asdrug particles 14 dissolve inmatrix 15 and diffuse therefrom, voids are left in the matrix. At such high drug loadings, the void volume is sufficient to make the portion of lamina 11 which has been v depleted of drug microporous. Such microporosity will cause the permeability of core lamina 11 to increase. Indeed, high drug loadings provide a means for making the permeability of the core lamina 11 substantially greater than the permeability of the outer laminas even though the same polymer is used in both. The drug loading of lamina 11 will'depend upon the drug dosage regimen desired, with higher loadings providing greater dosages and/or more sustained release. Usually the loading will be in the range of 30 to 75% by weight of the core lamina.
The nature of the drug will depend upon the therapy for which the device is intended. Drugs which produce a localized effect at the administration site or a systemic effect at a site remote from the administration site may be used. Such drugs include inorganic and organic compounds, for example, drugs which act on the central nervous system such as hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, antipyretics and anti-inflammatory agents, local. anesthetics,
anti-spasmodicsand antiulcer agents, prostaglandins,
anti-microbials, hormonal agents, estrogenic steroids, progestational steroids, such as for contraceptive purposes, sympathomimetic drugs, cardiovascular drugs, diuretics, anti-parasitic agents, hypoglycemic drugs and ophthalmic drugs.
Matrix material 15 may be made from a polymeric material which'is homogeneous and substantially imperforate (i.e., it has no man-made perforations) or it may be made from a polymer which has been made microporous by conventional techniques. In either instance its permeability to the drug should be known. (Known techniques are available to determine the permeabilitiesof such materials. See for instance US. Pat. No. 3,710,795.) Examplesof substantially imperforate polymers which may be used are poly(butylmethacrylate), plasticized poly(vinylchloride), plasticized soft nylon, natural rubber, poly(isoprene), poly(isobutylene), poly(butadiene), poly(ethylene), poly(vinylidene chloride), cross-linked poly(vinylpyrrolidone), chlorinated poly(ethylene), poly(4,4-isopropylidene diphenylene carbonate), ethylene-vinylacetate copolymer, plasticized ethylene-vinylacetate copolymer, vinlyidene chloride-acrylonitrile copolymer, vinyl chloride-diethyl fumerate copolymer, silicone rubbers, especially the medical grade poly(dimethylsiloxanes), ethylene-propylene rubber, silicone-carbonate copolymers and vinylidene chloridevinyl chloride copolymer.
Microporous materials have pores which range in size from at least about 10 A to several hundred microns, but usually not more than about 100 microns. Examples of materials from which microporous structures may be made are regenerated, insoluble, nonerodible cellulose, acylated cellulose, esterified cellulose, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate diethylaminoacetate, poly(urethanes), poly(carbonates), modified insoluble collagen, cross-linked poly(- vinyl alcohol), epoxy resins and poly(olefins) or poly(- vinylchlorides). These materials may be made microporous by well known procedures such as coprecipitation or leaching out incorporated salts, soap micelles, starch or like materials. See, for example, J. D. Ferry, Chemical Reviews, 18, 373 (1935), and In: Synthetic Polymer Membranes, by R. E. Kesting, McGraw-Hill, 1971.
Outer laminas 12,13 may be made from the same polymers asmatrix material 15, provided, of course, that the permeability of the material 15 to the drug is greater than the permeability of the material forming laminas, 12,13. It will be appreciated that either ofouter laminas 12,13 may be made from a drugimpermeable material. In such an instance, the effective thickness (the maximum thickness through which the drug must permeate to reach a permeable outer lamina) of core lamina 11 will be twice that of an embodiment in which both laminas 12,13 are drug permeable and the exposed outer lamina surface area from which drug is released will be half that of an embodiment in which both laminas 12,13 are drug permeable. It is also within the scope of this invention to makelaminas 12,13 from different polymeric materials of different drug permeability and to make them of different thicknesses.
The shape and size of the dispenser of this invention will depend upon the environment in which it is intended to be used. If the dispenser is intended to be implanted or inserted, its size and shape will be compatible with the size and shape of the implantation or insertion site. For instance, if it is intended to be used as an ocular insert, it will be sized and shaped for insertion and retention in the eye. Likewise, if intended for insertion in other body cavities, such as the vagina, uterus, mouth and gastrointestinal tract, it will be sized and shaped accordingly. In most instances it will be acceptable to employ regular shapes. As indicated above, the value of k in the expression will depend on the geometrical shape of the dispenser. For three-layered sandwich elliptical shaped dispensers such as dispenser 10, k has a value of 4. Its value for other sandwich-type dispensers of regular geometrical shape may be calculated, (e.g., for a circle it is 8). For cylindrical concentric laminate dispensers such as are listed above as useful fordispenser 19, k has a value of /s. The value of k for other concentric laminates of other cross-sectional shapes (e.g., hexagonal, square, elliptical) may be calculated.
The sandwich-type laminates of this invention may be manufactured according to well-known techniques. Depending upon the particular polymers comprising the core lamina and outer laminas, the laminate may be bonded together with or without binders. Various binders are well known in the art. See for instance the Encyclopedz'a of Polymer Science and Technology, John Wiley & Sons, Vol. 8, 1968. If a binder is used, it, of course, should be compatible with the polymers constituting the laminas and should not affect or interfere with the drug permeation through the laminas or alter the drug deleteriously in any manner. Conventional laminating machines and techniques may be used, with the particular temperatures and pressures employed varying with the polymers involved. The laminates may be formed as continuous sheets and the dispensers of this invention cut or punched therefrom by known techniques. The concentric-type laminates of the invention may also be formed by well-known techniques such as coextrusion.
While the dispensers have hereinabove been described as dispensers for releasing drugs for human or animal therapy, it will also be appreciated that they may be used to release other active agents in other environments, provided such agents are solid and have low water solubility as described above. Such active agents include, for example, pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promoters and inhibitors, preservatives, surfactants, disinfectants, catalysts, fermentation agents, nutrients, plant minerals, sex sterilants, plant hormones, air purifiers, microorganism attenuators and the like.
EXAMPLES The following examples illustrate the dispensers of this invention and their performance relative to dispensers outside the scope of the invention as defined herein, and are not intended to limit the scope of the invention in any manner.
Example 1 A. A physostigmine (Eserine) dispenser, such as might be inserted in the eye to dispense Eserine thereto, was made as follows. Fifty parts Eserine (particle size approximately 5 microns), and 50 parts of ethylene/vinyl acetate copolymer (brand name, Elvax 40) were mixed homogeneously on a rubber mill. The resulting mixture was melt pressed into a 200 micron thick film. This film was then placed in a vacuum/heat laminator and a 150 micron thick sheet of ethylene/vinyl acetate copolymer (brand name, Elvax 40) was laminated to each side of it. Duplicate 5.8 mm X 13.5 mm ellipses were punched from the resulting three layer laminate. P, P, A and A, for these elliptical dispensers were determined and the values for the expressions were calculated therefrom and are reported in Table 1 below.
B. Duplicate Eserine dispensers were made in accordance with part A above except that the outer laminas were each 75 microns thick. The data for these dispensers are also reported in Table 1 below.
C. For comparison, duplicate Eserine dispensers were made in accordance with part A above except 8 that the outer laminas were each 13 microns thick. The data for these dispensers are also reported in Table 1 below.
The release rates of the dispensers of A, B and C were determined by placing individual devices in polymer mesh bags and suspending the bags from a vertically reciprocating bar into vessels containing 50 ml water stirred at 37C. The Eserine concentration in the water was measured at regular intervals by UV analysis, the water being changed after each measurement. Eserine release rates were calculated from the measurements. FIG. 2 is a plot of these release rates versus time. As indicated by the plots of FIG. 2, the release rate of the dispensers of B is substantially more constant than that of the dispensers of C and that of A is even more constant than B. This is a reflection of the increasing value of the expression P r P as reported in Table 1.
Example 2 Two sets of chloramphenicol dispensers were made by the general procedure of Example 1A. The core lamina was made from 66 parts chloramphenicol (particle size approximately 5 microns) and 34 parts copolymer and was 125 microns thick. The outer laminas were 50 microns thick and 17.5 microns thick, respectively. The data for these two sets, designated 2A and 2B, are reported in Table 2 below.
Table 2 P P A A P I r k (A' )2 (cm (cmt P A 2A 16 0.1 1.23 4.5 605 2B 90 16 0.1 1.23l 6 605 The release rates of dispensers 2A and 2B were determined by the procedure described in Example 1. FIG. 3 is a plot of these release rates versus time.
Example 3 Table 3 P P A A P I k A 2 (cm) (cm I P A The release rates of dispensers 3A and 3B were determined by the procedure described in Example 1. FIG. 4 is a plot of these release rates versus time.
Modifications of the dispensers described herein which are obvious to persons of skill in the art are intended to be within the scope of the following claims.
We claim:
1. An active agent dispenser comprising a laminate of:
a. a core lamina of particles of a crystalline active agent of low water solubility dispersed in a solid material having a permeability, P, to the agent, the core lamina having a thickness 2t, and an exposed surface area, A, from which agent is released, and being partially covered by;
b. at least one outer lamina made of an active agent release rate controlling polymer having a permeability, P, to the agent, a thickness, 1, and an exposed surface area, A', from which agent is released wherein is greater than about 2 and is at least three times .L'... r P
10 is greater than 3 and is at least 10 times L. r P I 4. The drug dispenser ofclaim 2 wherein P is substantially greater than P.
5. The drug dispenser of claim 4 wherein P is substantially greater than P because of the porosity of the core lamina caused by the quantity of drug therein.
6. The drug dispenser ofclaim 2 wherein the drug initially comprises 30 to by weight of the core lamina.
7. The drug dispenser ofclaim 2 wherein the solubility of the drug in water is less than 4% by weight.
8; The drug dispenser ofclaim 2 wherein the drug is chloramphenicol, physostigmine or hydrocortisone, and the dispenser is sized and shaped for insertion in the cul-de-sac of a human eye.
9. The dispenser of claim 1 wherein the dispenser is a three layer sandwich-type laminate, said core lamina being sandwiched between a pair of said outer lamina.
10. The dispenser of claim 9 wherein the laminate has the geometrical shape of a thin circular disc and k is 8.
11. The dispenser of claim 9 wherein the laminate has the geometrical shape of a thin elliptical disc and k is 4.
12. The dispenser of claim 1 wherein the dispenser is a concentric-type laminate, said outer lamina being outerly concentric to said core lamina and covering the axial surface of said core lamina.
13. The dispenser ofclaim 12 wherein the laminate is cylindrical in shape and k has a value of Ma.

Claims (13)

US523720A1974-11-141974-11-14Laminated drug dispenserExpired - LifetimeUS3926188A (en)

Priority Applications (11)

Application NumberPriority DateFiling DateTitle
US523720AUS3926188A (en)1974-11-141974-11-14Laminated drug dispenser
GB4228975AGB1477813A (en)1974-11-141975-10-15Sustained release dispensers
DE2549856ADE2549856C2 (en)1974-11-141975-11-06 Active ingredient dispenser and process for its manufacture
IT69740/75AIT1050619B (en)1974-11-141975-11-06 PROLONGED DISPENSER DISPENSER PARTICULARLY FOR MEDICATIONS .. AND PROCEDURE FOR ITS MANUFACTURE
JP50136148AJPS6059203B2 (en)1974-11-141975-11-12 Manufacturing method of laminated dispenser
CA239,459ACA1056685A (en)1974-11-141975-11-12Active agent dispenser and process for making same
CH1472575ACH634226A5 (en)1974-11-141975-11-13 ACTIVE SUBSTANCE DISPENSER AND METHOD FOR THE PRODUCTION THEREOF.
SE7512744ASE439432B (en)1974-11-141975-11-13 PROCEDURE FOR THE PREPARATION OF A DEVICE FOR THE DELIVERY OF AN ACTIVE AGENT WITH LOW WATER SOLUBILITY THROUGH DIFFUSION FROM A POLYMER SKEL
MX6132AMX158867A (en)1974-11-141975-11-14 PROCEDURE FOR MAKING AN ACTIVE AGENT DISPENSER
FR7534821AFR2290891A1 (en)1974-11-141975-11-14 SUPPORT INTENDED TO SLOWLY RELEASE AN ACTIVE BODY, IN PARTICULAR A MEDICINAL PRODUCT, AND ITS MANUFACTURE
MX161923AMX158868A (en)1974-11-141975-11-14 ACTIVE AGENT DISPENSER

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US523720AUS3926188A (en)1974-11-141974-11-14Laminated drug dispenser

Publications (1)

Publication NumberPublication Date
US3926188Atrue US3926188A (en)1975-12-16

Family

ID=24086191

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US523720AExpired - LifetimeUS3926188A (en)1974-11-141974-11-14Laminated drug dispenser

Country Status (10)

CountryLink
US (1)US3926188A (en)
JP (1)JPS6059203B2 (en)
CA (1)CA1056685A (en)
CH (1)CH634226A5 (en)
DE (1)DE2549856C2 (en)
FR (1)FR2290891A1 (en)
GB (1)GB1477813A (en)
IT (1)IT1050619B (en)
MX (2)MX158868A (en)
SE (1)SE439432B (en)

Cited By (81)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4182330A (en)*1977-07-251980-01-08Alza CorporationMeans for administering amphipathic medicament
EP0025699A1 (en)*1979-09-121981-03-25Eli Lilly And CompanyDevice for drug delivery to ruminants
US4304232A (en)*1979-03-141981-12-08Alza CorporationUnit system having multiplicity of means for dispensing useful agent
US4314557A (en)*1980-05-191982-02-09Alza CorporationDissolution controlled active agent dispenser
DE3115763A1 (en)*1981-04-181982-11-04Edgar Dr.med. 6238 Hofheim LenhardMedical depot probe for the local protracted release of active substance
US4370313A (en)*1981-10-261983-01-25Eaton Laboratories, Inc.Nitrofurantoin dosage form
US4483846A (en)*1982-02-051984-11-20Ono Pharmaceutical Co., Ltd.Long-lasting three-layered pharmaceutical film preparations
US4552751A (en)*1980-10-171985-11-12Ono Pharmaceutical Co., Ltd.Long-lasting multi-layered film preparation
US4564364A (en)*1983-05-261986-01-14Alza CorporationActive agent dispenser
US4571039A (en)*1983-04-151986-02-18Stanley PolerEye-medicating contact-lens construction
DE3538038A1 (en)*1984-10-261986-04-30Alza Corp., Palo Alto, Calif. DEVICE FOR ADMINISTERING AN ACTIVE SUBSTANCE TO THE COLON
US4601893A (en)*1984-02-081986-07-22Pfizer Inc.Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4639244A (en)*1983-05-031987-01-27Nabil I. RizkImplantable electrophoretic pump for ionic drugs and associated methods
US4693895A (en)*1984-10-261987-09-15Alza CorporationColon delivery system
WO1989003232A1 (en)*1987-10-091989-04-20Bukh Meditec A/SA medical device for introduction into a body cavity
US4830860A (en)*1986-10-301989-05-16Pfizer Inc.Stressed polymeric device for controlled release of a substance to an ambient environment
US4841968A (en)*1986-09-261989-06-27Southern Research InstituteAntithrombotic/thrombolytic suture and methods of making and using the same
US4863445A (en)*1984-07-301989-09-05Baxter Travenol Laboratories, Inc.Assembly for inhibiting microbial growth in collected fluid
EP0293066A3 (en)*1987-05-271989-10-11Alza CorporationDispenser comprising displaceable matrix with solid state properties
US4880633A (en)*1986-03-121989-11-14Merck & Co., Inc.Transdermal drug delivery system
US4906475A (en)*1988-02-161990-03-06Paco Pharmaceutical ServicesEstradiol transdermal delivery system
US4908027A (en)*1986-09-121990-03-13Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US4938759A (en)*1986-09-021990-07-03Alza CorporationTransdermal delivery device having a rate controlling adhesive
US4959208A (en)*1987-10-191990-09-25Ppg Industries, Inc.Active agent delivery device
US4973468A (en)*1989-03-221990-11-27Cygnus Research CorporationSkin permeation enhancer compositions
US4994275A (en)*1988-07-051991-02-19Pfizer Inc.Veterinary devices
US5004610A (en)*1988-06-141991-04-02Alza CorporationSubsaturated nicotine transdermal therapeutic system
US5035886A (en)*1987-10-191991-07-30Ppg Industries, Inc.Active agent delivery device
US5053227A (en)*1989-03-221991-10-01Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en)*1989-03-221991-10-22Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5071645A (en)*1987-10-191991-12-10Ppg Industries, Inc.Process of producing an active agent delivery device
US5088505A (en)*1987-08-081992-02-18Akzo N.V.Contraceptive implant
WO1992002211A1 (en)*1990-08-091992-02-20Endocon, Inc.Multiple drug delivery system
US5124157A (en)*1989-08-181992-06-23Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
US5217718A (en)*1989-08-181993-06-08Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
US5342623A (en)*1986-09-121994-08-30Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US5466233A (en)*1994-04-251995-11-14Escalon Ophthalmics, Inc.Tack for intraocular drug delivery and method for inserting and removing same
US5508038A (en)*1990-04-161996-04-16Alza CorporationPolyisobutylene adhesives for transdermal devices
EP0710491A1 (en)*1994-11-021996-05-08The Population Council, Center For Biomedical ResearchSubdermally implantable device
EP0684815A4 (en)*1993-02-191997-04-23Sam S AhnDrug delivery system using hollow fibers.
US20020148138A1 (en)*2001-04-062002-10-17Egan Brian A.Smart tread boot covers
US20030157140A1 (en)*2000-05-262003-08-21Kanji TakadaNonoral preparation having three-layer structure
US20040210208A1 (en)*2003-04-162004-10-21Cook IncorporatedMedical device with therapeutic agents
WO2005110364A3 (en)*2004-04-302006-07-13Allergan IncDrug delivery systems and methods for treatment of an eye
WO2006040141A3 (en)*2004-10-122006-10-05Capsulution Nanoscience AgSegmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof
US20070043332A1 (en)*2003-07-102007-02-22Galen (Chemiclas) LiimitedIntravaginal drug delivery devices
USRE39588E1 (en)1987-11-092007-04-24Alza CorporationTransdermal drug delivery device
US7585517B2 (en)*2003-09-182009-09-08Macusight, Inc.Transscleral delivery
US20110066141A1 (en)*2009-09-112011-03-17Cook IncorporatedImplantable medical device having an anti-gastric distress agent
US20110098797A1 (en)*2009-10-232011-04-28Cleek Robert LDrug eluting composite
US20110112618A1 (en)*2009-11-092011-05-12Cleek Robert LDrug eluting composite
WO2011116132A1 (en)2010-03-162011-09-22Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US8222271B2 (en)2006-03-232012-07-17Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8277830B2 (en)2009-01-292012-10-02Forsight Vision4, Inc.Posterior segment drug delivery
US8367097B2 (en)2005-02-092013-02-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8486052B2 (en)2001-06-122013-07-16The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US8492400B2 (en)2006-02-092013-07-23Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8623395B2 (en)2010-01-292014-01-07Forsight Vision4, Inc.Implantable therapeutic device
US8663639B2 (en)2005-02-092014-03-04Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US8715712B2 (en)2011-09-142014-05-06Forsight Vision5, Inc.Ocular insert apparatus and methods
US20140271783A1 (en)*2011-10-142014-09-18Purdue Research FoundationPrefabricated pharmaceutical dosage forms from functional polymer films
US8905963B2 (en)2010-08-052014-12-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US20160067178A1 (en)*2014-09-082016-03-10ProMed Pharma, LLCMethods for manufacturing implants
US9421126B2 (en)2009-06-032016-08-23Forsight Vision5, Inc.Anterior segment drug delivery
US9474756B2 (en)2014-08-082016-10-25Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en)2010-08-052016-11-15Forsight Vision4, Inc.Implantable therapeutic device
US9504771B2 (en)2009-11-092016-11-29W. L. Gore & Associates, Inc.Drug eluting composite
US9526654B2 (en)2013-03-282016-12-27Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US9750636B2 (en)2012-10-262017-09-05Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US9883968B2 (en)2011-09-162018-02-06Forsight Vision4, Inc.Fluid exchange apparatus and methods
US9968603B2 (en)2013-03-142018-05-15Forsight Vision4, Inc.Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10166142B2 (en)2010-01-292019-01-01Forsight Vision4, Inc.Small molecule delivery with implantable therapeutic device
US10398592B2 (en)2011-06-282019-09-03Forsight Vision4, Inc.Diagnostic methods and apparatus
US10500091B2 (en)2014-11-102019-12-10Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US10617557B2 (en)2010-08-052020-04-14Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US10874548B2 (en)2010-11-192020-12-29Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US11224602B2 (en)2015-04-132022-01-18Forsight Vision5, Inc.Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11419759B2 (en)2017-11-212022-08-23Forsight Vision4, Inc.Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en)2015-11-202022-09-06Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US11617680B2 (en)2016-04-052023-04-04Forsight Vision4, Inc.Implantable ocular drug delivery devices
USD1033637S1 (en)2022-01-242024-07-02Forsight Vision4, Inc.Fluid exchange device

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CH667001A5 (en)*1985-09-031988-09-15Hugo Degen UNDER MATTRESS.
JPS63143581A (en)*1986-12-051988-06-15Nissha Printing Co LtdHologram molded article
JPH0444666U (en)*1990-08-221992-04-15
JPH0444601U (en)*1990-08-221992-04-15
JP3720386B2 (en)*1993-12-272005-11-24住友製薬株式会社 Drug release controlled formulation

Citations (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2928770A (en)*1958-11-281960-03-15Frank M BardaniSustained action pill
US3184386A (en)*1958-05-021965-05-18Burroughs Wellcome CoProlonged action medicinal tablets
US3416530A (en)*1966-03-021968-12-17Richard A. NessEyeball medication dispensing tablet
US3618604A (en)*1969-06-091971-11-09Alza CorpOcular insert
US3625214A (en)*1970-05-181971-12-07Alza CorpDrug-delivery device
US3797485A (en)*1971-03-261974-03-19Alza CorpNovel drug delivery device for administering drug into blood circulation in blood vessel
US3851648A (en)*1973-10-111974-12-03Mead Johnson & CoZero-order release device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3854480A (en)*1969-04-011974-12-17Alza CorpDrug-delivery system
US3630200A (en)*1969-06-091971-12-28Alza CorpOcular insert
US3832252A (en)*1970-09-291974-08-27T HiguchiMethod of making a drug-delivery device

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3184386A (en)*1958-05-021965-05-18Burroughs Wellcome CoProlonged action medicinal tablets
US2928770A (en)*1958-11-281960-03-15Frank M BardaniSustained action pill
US3416530A (en)*1966-03-021968-12-17Richard A. NessEyeball medication dispensing tablet
US3618604A (en)*1969-06-091971-11-09Alza CorpOcular insert
US3625214A (en)*1970-05-181971-12-07Alza CorpDrug-delivery device
US3797485A (en)*1971-03-261974-03-19Alza CorpNovel drug delivery device for administering drug into blood circulation in blood vessel
US3851648A (en)*1973-10-111974-12-03Mead Johnson & CoZero-order release device

Cited By (141)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4182330A (en)*1977-07-251980-01-08Alza CorporationMeans for administering amphipathic medicament
US4304232A (en)*1979-03-141981-12-08Alza CorporationUnit system having multiplicity of means for dispensing useful agent
EP0025699A1 (en)*1979-09-121981-03-25Eli Lilly And CompanyDevice for drug delivery to ruminants
US4314557A (en)*1980-05-191982-02-09Alza CorporationDissolution controlled active agent dispenser
US4552751A (en)*1980-10-171985-11-12Ono Pharmaceutical Co., Ltd.Long-lasting multi-layered film preparation
DE3115763A1 (en)*1981-04-181982-11-04Edgar Dr.med. 6238 Hofheim LenhardMedical depot probe for the local protracted release of active substance
US4370313A (en)*1981-10-261983-01-25Eaton Laboratories, Inc.Nitrofurantoin dosage form
US4483846A (en)*1982-02-051984-11-20Ono Pharmaceutical Co., Ltd.Long-lasting three-layered pharmaceutical film preparations
US4571039A (en)*1983-04-151986-02-18Stanley PolerEye-medicating contact-lens construction
US4639244A (en)*1983-05-031987-01-27Nabil I. RizkImplantable electrophoretic pump for ionic drugs and associated methods
US4564364A (en)*1983-05-261986-01-14Alza CorporationActive agent dispenser
US4601893A (en)*1984-02-081986-07-22Pfizer Inc.Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4863445A (en)*1984-07-301989-09-05Baxter Travenol Laboratories, Inc.Assembly for inhibiting microbial growth in collected fluid
DE3538038A1 (en)*1984-10-261986-04-30Alza Corp., Palo Alto, Calif. DEVICE FOR ADMINISTERING AN ACTIVE SUBSTANCE TO THE COLON
US4693895A (en)*1984-10-261987-09-15Alza CorporationColon delivery system
US4880633A (en)*1986-03-121989-11-14Merck & Co., Inc.Transdermal drug delivery system
US4938759A (en)*1986-09-021990-07-03Alza CorporationTransdermal delivery device having a rate controlling adhesive
US5342623A (en)*1986-09-121994-08-30Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en)*1986-09-121990-03-13Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US4841968A (en)*1986-09-261989-06-27Southern Research InstituteAntithrombotic/thrombolytic suture and methods of making and using the same
US4830860A (en)*1986-10-301989-05-16Pfizer Inc.Stressed polymeric device for controlled release of a substance to an ambient environment
EP0293066A3 (en)*1987-05-271989-10-11Alza CorporationDispenser comprising displaceable matrix with solid state properties
US5088505A (en)*1987-08-081992-02-18Akzo N.V.Contraceptive implant
WO1989003232A1 (en)*1987-10-091989-04-20Bukh Meditec A/SA medical device for introduction into a body cavity
US4959208A (en)*1987-10-191990-09-25Ppg Industries, Inc.Active agent delivery device
US5035886A (en)*1987-10-191991-07-30Ppg Industries, Inc.Active agent delivery device
US5071645A (en)*1987-10-191991-12-10Ppg Industries, Inc.Process of producing an active agent delivery device
USRE39588E1 (en)1987-11-092007-04-24Alza CorporationTransdermal drug delivery device
US4906475A (en)*1988-02-161990-03-06Paco Pharmaceutical ServicesEstradiol transdermal delivery system
US5633008A (en)*1988-06-141997-05-27Osborne; James L.Method of administering nicotine transdermally
US5004610A (en)*1988-06-141991-04-02Alza CorporationSubsaturated nicotine transdermal therapeutic system
US6165497A (en)*1988-06-142000-12-26Alza CorporationSubsaturated nicotine transdermal therapeutic system
US4994275A (en)*1988-07-051991-02-19Pfizer Inc.Veterinary devices
US5059426A (en)*1989-03-221991-10-22Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en)*1989-03-221991-10-01Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en)*1989-03-221990-11-27Cygnus Research CorporationSkin permeation enhancer compositions
US5124157A (en)*1989-08-181992-06-23Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
US5217718A (en)*1989-08-181993-06-08Cygnus Therapeutic SystemsMethod and device for administering dexmedetomidine transdermally
LT3753B (en)1989-08-181996-03-25Cygnus Therapeutic SystemDevice for administering dexmedetomidine transdermally
US5508038A (en)*1990-04-161996-04-16Alza CorporationPolyisobutylene adhesives for transdermal devices
WO1992002211A1 (en)*1990-08-091992-02-20Endocon, Inc.Multiple drug delivery system
EP0684815A4 (en)*1993-02-191997-04-23Sam S AhnDrug delivery system using hollow fibers.
US5466233A (en)*1994-04-251995-11-14Escalon Ophthalmics, Inc.Tack for intraocular drug delivery and method for inserting and removing same
EP0710491A1 (en)*1994-11-021996-05-08The Population Council, Center For Biomedical ResearchSubdermally implantable device
US5660848A (en)*1994-11-021997-08-26The Population Council, Center For Biomedical ResearchSubdermally implantable device
US5756115A (en)*1994-11-021998-05-26The Population Coucil, Center For Biomedical ResearchContraceptive method using a subdermally implantable device
US7695729B2 (en)*2000-05-262010-04-13Kanji TakadaNonoral preparation having three-layer structure
US20030157140A1 (en)*2000-05-262003-08-21Kanji TakadaNonoral preparation having three-layer structure
US20020148138A1 (en)*2001-04-062002-10-17Egan Brian A.Smart tread boot covers
US9180046B2 (en)2001-06-122015-11-10The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US9522082B2 (en)2001-06-122016-12-20The Johns Hopkins UniversityReservoir device for intraocular drug delivery
US10470924B2 (en)2001-06-122019-11-12The Johns Hopkins UniversityReservoir device for intraocular drug delivery
US8486052B2 (en)2001-06-122013-07-16The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US7306580B2 (en)2003-04-162007-12-11Cook IncorporatedMedical device with therapeutic agents
US20040210208A1 (en)*2003-04-162004-10-21Cook IncorporatedMedical device with therapeutic agents
US7780647B2 (en)2003-04-162010-08-24Cook IncorporatedMedical device with therapeutic agents
WO2004093962A1 (en)*2003-04-162004-11-04Cook IncorporatedMedical device with therapeutic agents.
US20080051737A1 (en)*2003-04-162008-02-28Cook IncorporatedMedical device with therapeutic agents
US20070043332A1 (en)*2003-07-102007-02-22Galen (Chemiclas) LiimitedIntravaginal drug delivery devices
US7585517B2 (en)*2003-09-182009-09-08Macusight, Inc.Transscleral delivery
WO2005110364A3 (en)*2004-04-302006-07-13Allergan IncDrug delivery systems and methods for treatment of an eye
US20090117170A1 (en)*2004-10-122009-05-07Capsulution Nanoscience AgSegmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof
WO2006040141A3 (en)*2004-10-122006-10-05Capsulution Nanoscience AgSegmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof
US9381153B2 (en)2005-02-092016-07-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8927005B2 (en)2005-02-092015-01-06Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8663639B2 (en)2005-02-092014-03-04Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US8367097B2 (en)2005-02-092013-02-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US9387165B2 (en)2005-02-092016-07-12Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US8637070B2 (en)2005-02-092014-01-28Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US8658667B2 (en)2006-02-092014-02-25Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8492400B2 (en)2006-02-092013-07-23Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8486960B2 (en)2006-03-232013-07-16Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8222271B2 (en)2006-03-232012-07-17Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US9452156B2 (en)2006-03-232016-09-27Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US10813788B2 (en)2009-01-292020-10-27Forsight Vision4, Inc.Implantable therapeutic device
US9066779B2 (en)2009-01-292015-06-30Forsight Vision4, Inc.Implantable therapeutic device
US8795712B2 (en)2009-01-292014-08-05Forsight Vision4, Inc.Posterior segment drug delivery
US8808727B2 (en)2009-01-292014-08-19Forsight Vision4, Inc.Posterior segment drug delivery
US9851351B2 (en)2009-01-292017-12-26Forsight Vision4, Inc.Posterior segment drug delivery
US8399006B2 (en)2009-01-292013-03-19Forsight Vision4, Inc.Posterior segment drug delivery
US8277830B2 (en)2009-01-292012-10-02Forsight Vision4, Inc.Posterior segment drug delivery
US10656152B2 (en)2009-01-292020-05-19Forsight Vision4, Inc.Posterior segment drug delivery
US8298578B2 (en)2009-01-292012-10-30Forsight Vision4, Inc.Posterior segment drug delivery
US9417238B2 (en)2009-01-292016-08-16Forsight Vision4, Inc.Posterior segment drug delivery
US11642310B2 (en)2009-01-292023-05-09Forsight Vision4, Inc.Posterior segment drug delivery
US9421126B2 (en)2009-06-032016-08-23Forsight Vision5, Inc.Anterior segment drug delivery
US10736774B2 (en)2009-06-032020-08-11Forsight Vision5, Inc.Anterior segment drug delivery
US10004636B2 (en)2009-06-032018-06-26Forsight Vision5, Inc.Anterior segment drug delivery
US20110066141A1 (en)*2009-09-112011-03-17Cook IncorporatedImplantable medical device having an anti-gastric distress agent
US20110098797A1 (en)*2009-10-232011-04-28Cleek Robert LDrug eluting composite
US20110112618A1 (en)*2009-11-092011-05-12Cleek Robert LDrug eluting composite
US9320890B2 (en)2009-11-092016-04-26W. L. Gore & Associates, Inc.Drug eluting composite
US10039863B2 (en)2009-11-092018-08-07W. L. Gore & Associates, Inc.Drug eluting composite
US9504771B2 (en)2009-11-092016-11-29W. L. Gore & Associates, Inc.Drug eluting composite
US10166142B2 (en)2010-01-292019-01-01Forsight Vision4, Inc.Small molecule delivery with implantable therapeutic device
US8623395B2 (en)2010-01-292014-01-07Forsight Vision4, Inc.Implantable therapeutic device
US10111830B2 (en)2010-03-162018-10-30Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
WO2011116132A1 (en)2010-03-162011-09-22Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US10123971B2 (en)2010-03-162018-11-13Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US9937073B2 (en)2010-06-012018-04-10Forsight Vision5, Inc.Ocular insert apparatus and methods
US8939948B2 (en)2010-06-012015-01-27Forsight Vision5, Inc.Ocular insert apparatus and methods
US10265215B2 (en)2010-08-052019-04-23Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US11786396B2 (en)2010-08-052023-10-17Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US8905963B2 (en)2010-08-052014-12-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US9492315B2 (en)2010-08-052016-11-15Forsight Vision4, Inc.Implantable therapeutic device
US11679027B2 (en)2010-08-052023-06-20Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US9861521B2 (en)2010-08-052018-01-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US10617557B2 (en)2010-08-052020-04-14Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US9033911B2 (en)2010-08-052015-05-19Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US10874548B2 (en)2010-11-192020-12-29Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US11065151B2 (en)2010-11-192021-07-20Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US10398592B2 (en)2011-06-282019-09-03Forsight Vision4, Inc.Diagnostic methods and apparatus
US11813196B2 (en)2011-06-282023-11-14Forsight Vision4, Inc.Diagnostic methods and apparatus
US8715712B2 (en)2011-09-142014-05-06Forsight Vision5, Inc.Ocular insert apparatus and methods
US10835416B2 (en)2011-09-142020-11-17Forsight Vision5, Inc.Ocular insert apparatus and methods
US9883968B2 (en)2011-09-162018-02-06Forsight Vision4, Inc.Fluid exchange apparatus and methods
US10653554B2 (en)2011-09-162020-05-19Forsight Vision4, Inc.Fluid exchange apparatus and methods
US20140271783A1 (en)*2011-10-142014-09-18Purdue Research FoundationPrefabricated pharmaceutical dosage forms from functional polymer films
US9750636B2 (en)2012-10-262017-09-05Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US10456293B2 (en)2012-10-262019-10-29Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US9968603B2 (en)2013-03-142018-05-15Forsight Vision4, Inc.Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11510810B2 (en)2013-03-282022-11-29Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en)2013-03-282024-10-15Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en)2013-03-282019-09-03Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US9526654B2 (en)2013-03-282016-12-27Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US10765677B2 (en)2014-08-082020-09-08Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en)2014-08-082019-07-30Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en)2014-08-082018-02-20Forsight Vision4, IncStable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9474756B2 (en)2014-08-082016-10-25Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10226419B2 (en)*2014-09-082019-03-12ProMed Pharma, LLCMethods for manufacturing implants
US20160067178A1 (en)*2014-09-082016-03-10ProMed Pharma, LLCMethods for manufacturing implants
US11110001B2 (en)2014-11-102021-09-07Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US10500091B2 (en)2014-11-102019-12-10Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US12251336B2 (en)2014-11-102025-03-18Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US11224602B2 (en)2015-04-132022-01-18Forsight Vision5, Inc.Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11432959B2 (en)2015-11-202022-09-06Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US12201556B2 (en)2015-11-202025-01-21Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US11617680B2 (en)2016-04-052023-04-04Forsight Vision4, Inc.Implantable ocular drug delivery devices
US12102560B2 (en)2016-04-052024-10-01Forsight Vision4, Inc.Implantable ocular drug delivery devices
US11419759B2 (en)2017-11-212022-08-23Forsight Vision4, Inc.Fluid exchange apparatus for expandable port delivery system and methods of use
USD1033637S1 (en)2022-01-242024-07-02Forsight Vision4, Inc.Fluid exchange device

Also Published As

Publication numberPublication date
SE7512744L (en)1977-05-15
IT1050619B (en)1981-03-20
DE2549856A1 (en)1976-05-20
JPS6059203B2 (en)1985-12-24
MX158867A (en)1989-03-27
FR2290891A1 (en)1976-06-11
CH634226A5 (en)1983-01-31
FR2290891B1 (en)1978-11-10
SE439432B (en)1985-06-17
MX158868A (en)1989-03-27
DE2549856C2 (en)1985-01-03
GB1477813A (en)1977-06-29
CA1056685A (en)1979-06-19
JPS5170807A (en)1976-06-18

Similar Documents

PublicationPublication DateTitle
US3926188A (en)Laminated drug dispenser
US3995631A (en)Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4278087A (en)Device with integrated operations for controlling release of agent
US4034756A (en)Osmotically driven fluid dispenser
US4177256A (en)Osmotic bursting drug delivery device
CA1047403A (en)Process for making a monolithic drug delivery device
US3845770A (en)Osmatic dispensing device for releasing beneficial agent
US4142526A (en)Osmotic releasing system with means for changing release therefrom
US3760805A (en)Osmotic dispenser with collapsible supply container
EP0266929B1 (en)Stressed polymeric device for controlled release of a substance to an ambient environment
US3916899A (en)Osmotic dispensing device with maximum and minimum sizes for the passageway
US3760984A (en)Osmotically powered agent dispensing device with filling means
US3760806A (en)Helical osmotic dispenser with non-planar membrane
US4111202A (en)Osmotic system for the controlled and delivery of agent over time
US4573996A (en)Device for the administration of an active agent to the skin or mucosa
AU670410B2 (en)Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US4601893A (en)Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US3760804A (en)Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US4327725A (en)Osmotic device with hydrogel driving member
US4067961A (en)Controlled release article
US4786500A (en)Programmable agent delivery system
US4127127A (en)Therapeutic systems made from certain segmented copolyesters
GB1565678A (en)Implatable vaginal medicament dispenser
GB1565677A (en)Implantable vaginal medicament dispenser
IE61788B1 (en)Transdermal therapeutic system

[8]ページ先頭

©2009-2025 Movatter.jp